[Case of agrypnia (4 months without sleep) in Morvan's disease. Favorable action of 5-hydroxytryptophan]

Electroencephalogr Clin Neurophysiol. 1974 Jan;36(1):1-18. doi: 10.1016/0013-4694(74)90132-1.
[Article in French]
No abstract available

MeSH terms

  • 5-Hydroxytryptophan / administration & dosage
  • 5-Hydroxytryptophan / adverse effects
  • 5-Hydroxytryptophan / therapeutic use*
  • Adult
  • Chorea / complications*
  • Chorea / drug therapy
  • Dose-Response Relationship, Drug
  • Electroconvulsive Therapy
  • Electroencephalography
  • Hallucinations / etiology
  • Humans
  • Hydroxyindoleacetic Acid / urine
  • Hypnotics and Sedatives / therapeutic use
  • Leg*
  • Male
  • Memory Disorders / etiology
  • Myoclonus / complications*
  • Myoclonus / drug therapy
  • Sleep Deprivation
  • Sleep Initiation and Maintenance Disorders / drug therapy
  • Sleep Initiation and Maintenance Disorders / etiology*
  • Sleep Stages
  • Sleep, REM
  • Time Factors
  • Tryptophan / therapeutic use
  • Wakefulness

Substances

  • Hypnotics and Sedatives
  • Hydroxyindoleacetic Acid
  • Tryptophan
  • 5-Hydroxytryptophan